What top creators are saying about Recursion Pharmaceuticals, Inc.(RXRX)

Offers public-market exposure to AI-enabled drug research, but the transcript gives limited company-specific evidence about valuation, pipeline results, or clinical milestones.

Used as an example of a stock for which the speaker thought the market was misjudging the company; no position, valuation, or specific recommendation was stated.

The speaker described Recursion as an attractive short, citing concerns about pipeline quality and differentiation, competition, cash burn, dilution, and valuation.

The speaker called RXRX a good short, citing uncertain pipeline value, doubts about its AI platform, high cash burn, dilution, and concerns about execution. REC-7735 was described as a potentially interesting candidate, but its differentiation and development prospects were questioned.

The speaker said he had been short for years, viewed the company as unconvincing and overvalued, but acknowledged that the short had not worked well.

Speakers called the company weak, anticipated it might finish the day lower, and criticized reliance on an AI label rather than evidence that its drug programs work; it was also described as dropping sharply.

The speaker called the stock a compelling short, citing an unsupported valuation, concerns about pipeline quality and the AI platform, substantial cash burn, potential dilution, and competition in its PI3K-alpha program.

The host called the company a 'total shitshow' and argued that its AI connection does not establish that its drugs will succeed.

The host called Recursion a short and criticized its AI-focused drug-development approach, but offered no detailed analysis of its pipeline or finances.

NVIDIA's 13F filing revealed it sold its entire stake in the company as part of a portfolio rebalancing.

JPMorgan upgraded the stock to Overweight, citing blockbuster potential for its drug REC-4881 and strong efficacy for REC-617, suggesting a potential 3x return.

Identified as a potential short squeeze candidate due to a 30% short interest and positive AI-developed drug data, despite dilution concerns. A 'max bearish' call from Jim Cramer is noted as a potential contrarian indicator.

Announced positive Phase 1b/2 results for its AI-developed drug REC-4881. Considered a potentially attractive opportunity due to positive news, investor interest from NVIDIA, and high (40%) short interest.

Set to release critical clinical data from its TUPELO Phase 1b/2 trial on December 8, 2025. The decision to host a webinar suggests potential confidence in positive data, which could trigger a significant price movement and a potential short squeeze.

NVIDIA's investment in the company highlights a strategic interest in the application of AI for drug discovery and the broader healthcare sector.

Mentioned as one of the heavily shorted, smaller-cap stocks that saw significant gains due to a 'risk-on' appetite and speculative fervor in the market.

Speaker is shorting the stock and believes it is 'basically worthless'.